Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469908 | 0.91 | CA2 (0.41) | APPALDH1A1CA2PTGS1PDE4A | |
| SCHEMBL9813894 | 0.91 | CA2 (0.41) | APPALDH1A1CA2PTGS1PDE4A | |
| SCHEMBL3177040 | 0.91 | — | — | |
| SCHEMBL10324781 | 0.89 | APP (0.44) | APPALDH1A1PTGS1PDE4ALMNA | |
| Hydrochloric Acid SCHEMBL5063686 | 0.89 | APP (0.44) | APPALDH1A1PTGS1PDE4ALMNA | |
| SCHEMBL20875302 | 0.89 | APP (0.48) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL421993 | 0.86 | APP (0.50) | APPALDH1A1PTGS1PDE4ALMNA | |
| SCHEMBL14114300 | 0.85 | CA2 (0.40) | APPALDH1A1CA2PTGS1PDE4A | |
| SCHEMBL14195598 | 0.85 | CA2 (0.40) | APPALDH1A1CA2PTGS1PDE4A | |
| SCHEMBL864101 | 0.84 | APP (0.44) | APPALDH1A1PTGS1PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772438-B2 | Preparation of polyamides | Invista North America S.är.l. (US) | 2014-07-08 | — | — | US | claimed |
| US-20120264907-A1 | PREPARATION OF POLYAMIDES | INVISTA NORTH AMERICA S.A.R.L. (US) | 2012-10-18 | — | — | US | claimed |
| EP-2451863-A1 | PREPARATION OF POLYAMIDES | Invista Technologies S.A R.L. (CH) | 2012-05-16 | — | — | EP | claimed |
| WO-2011004138-A1 | PREPARATION OF POLYAMIDES | INVISTA TECHNOLOGIES S.A.R.L. (CH) | 2011-01-13 | — | — | WO | claimed |
| EP-2640686-B1 | NITROUS OXIDE-CONTAINING IONIC LIQUIDS AS CHEMICAL REAGENTS | INVISTA TECH SARL (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-8772438-B2 | Preparation of polyamides | Invista North America S.är.l. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130299738-A1 | NITROUS OXIDE-CONTAINING IONIC LIQUIDS AS CHEMICAL REAGENTS | INVISTA NORTH AMERICA S.A.R.L. (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2640686-A2 | NITROUS OXIDE-CONTAINING IONIC LIQUIDS AS CHEMICAL REAGENTS | Invista Technologies S.A R.L. (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2456807-B1 | SYNTHESIS METHOD USING IONIC LIQUIDS | INVISTA TECH SARL (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120264907-A1 | PREPARATION OF POLYAMIDES | INVISTA NORTH AMERICA S.A.R.L. (US) | 2012-10-18 | — | — | US | disclosed |
| EP-2456807-A2 | SYNTHESIS METHOD USING IONIC LIQUIDS | Invista Technologies S.A R.L. (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012066296-A2 | NITROUS OXIDE-CONTAINING IONIC LIQUIDS AS CHEMICAL REAGENTS | INVISTA TECHNOLOGIES S.A.R. L. (CH) | 2012-05-24 | — | — | WO | disclosed |
| EP-2451863-A1 | PREPARATION OF POLYAMIDES | Invista Technologies S.A R.L. (CH) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011010116-A2 | SYNTHESIS METHOD USING IONIC LIQUIDS | INVISTA TECHNOLOGIES S.À.R.L. (CH) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011004138-A1 | PREPARATION OF POLYAMIDES | INVISTA TECHNOLOGIES S.A.R.L. (CH) | 2011-01-13 | — | — | WO | disclosed |
| EP-2051788-A1 | EXTRACTION PROCESS USING AN IONIC LIQUID | Invista Technologies S.à.r.l. (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-7442841-B2 | Extraction process | INVISTA NORTH AMERICA S.A R.L. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080051609-A1 | EXTRACTION PROCESS | INVISTA NORTH AMERICA S.A.R.L. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008022233-A1 | EXTRACTION PROCESS USING AN IONIC LIQUID | INVISTA TECHNOLOGIES S.A.R.L. (CH) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051609-A1 | EXTRACTION PROCESS | ADH1C, ADH1A, ADH5 | APP 1637/4885ALDH1A1 825/4885CA2 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.